Introduction {#sec1}
============

Major depressive disorder (MDD) affects around 300 million people worldwide and becomes a leading burden of the economy ([@ref18]). The core symptoms of MDD include depressed mood, lack of interest, difficulties in concentration, changes in appetite and sleep, and cognitive impairment ([@ref2]). The treatment for depression is challenging as approximately 30% of MDD patients develop treatment-resistant depression (TRD) despite subsequent antidepressant augmentations or switches ([@ref34]). The development of TRD is mainly due to our limited understanding of the neurobiology of MDD and the action mechanism of antidepressant treatment ([@ref15]). It was supposed that antidepressants exert their acute effects primarily by increasing the availability of serotonin (5-HT), norepinephrine (NE), or both in the synaptic cleft ([@ref3]). Although antidepressants immediately increase the monoamine levels in the brain, it takes at least 2--3 weeks for the occurrence of mood-enhancing effects, thereby indicating other mechanisms may contribute to its efficiency.

MDD is considered a complex brain disorder resulting from abnormal brain structural and functional connectivity ([@ref14]). White matter tracts are critical for interconnecting brain regions and transferring the neural activities essential for organizing human behavior, emotions, and cognition ([@ref12]). Neuroimaging studies have shown white matter abnormalities in the brains of patients with MDD ([@ref49]; [@ref8]). Oligodendrocytes (OLs) are residential glial cells responsible for generating myelin sheaths and white matter tracts in the central nervous system (CNS) ([@ref28]). Abnormalities in myelin and OL are associated with cognitive impairment and increased suicide attempts in MDD patients ([@ref49]; [@ref8]).

Multiple sclerosis (MS) is a demyelinating inflammatory disorder. Over half of MS patients exhibit MDD comorbidity ([@ref11]), thereby suggesting some biological abnormalities (e.g., deficits of myelin and OL and neuroinflammation) may coexist in MDD and MS ([@ref26]). While a variety of treatments including antidepressants, psychotherapy, and neuromodulation have shown therapeutic effects due to the improvement of the white matter structure and function ([@ref27]; [@ref51]; [@ref45]; [@ref1]), cases with severe white matter changes showed poor responses to antidepressant treatment ([@ref31]; [@ref35]). Together, these findings suggest white matter/myelin integrity is a new treatment target for MS and MDD, especially for treatment-resistant depression ([@ref35]).

Venlafaxine, a serotonin and noradrenaline reuptake inhibitor (SNRI) antidepressant, has been widely used for MDD, anxiety, and neuropathy ([@ref41]; [@ref44]). Venlafaxine is also a preferred choice for monotherapy or combination treatment for TRD ([@ref41]). Studies found that venlafaxine possesses the neuroprotective effects *via* its anti-inflammatory activities ([@ref47]; [@ref6]). Our previous research showed that desvenlafaxine, a major active metabolite of venlafaxine, prevented stress-induced white matter injuries in mice ([@ref46]). However, it is unknown whether venlafaxine can provide neural protections by acting on OLs and preserve myelin integrity. The cuprizone-induced demyelinated mice showing white matter deficits and cognitive and emotional impairments with minimal motor function deficits ([@ref53]; [@ref50]) are a suitable animal model in our present study to explore the effects of venlafaxine on behavioral abnormalities, myelination/OL deficits, and neuroinflammation.

Materials and Methods {#sec2}
=====================

Animals {#sec3}
-------

Seven-week-old female C57BL/6 mice were purchased from Charles River (Montreal, Canada) and hosted in the animal facility maintained at a 12-h/12-h light--dark cycle, at 22 ± 0.5°C and 60% humidity, with *ad lib* to food and water. All animal procedures were performed under the Canadian Council on Animal Care (CCAC) guidelines and were approved by the University Committee on Animal Care and Supply (UCACS) of the University of Saskatchewan. Mice develop selective central demyelination and inflammation in the prefrontal cortex, hippocampus, and the corpus callosum (CC) after 5 weeks of CPZ treatment ([@ref52]).

Drug Treatment {#sec4}
--------------

Cuprizone (CPZ, Sigma-Aldrich, St. Louis, MO, USA) was mixed into the milled Lab Diet rodent chow (PMI Nutrition International LLC, Brentwood, MO, USA) with a final concentration of 0.2% (w/w), as previously described ([@ref52]). Venlafaxine (Pfizer, Montreal, Canada) was dissolved in distilled water. After acclimatization with the regular rodent diet for 1 week, mice were divided into six groups (16 mice per group). Mice in the first three groups received regular chows plus daily treatment with either water (CTL), or 5 mg/kg/day of venlafaxine (VEN5), or 20 mg/kg/day of venlafaxine (VEN20) for 5 weeks. The remaining groups received rodent chows containing 0.2% CPZ (w/w) plus daily treatment with either water (CPZ), or venlafaxine 5 mg/kg/day (CPZ + VEN5), or venlafaxine 20 mg/kg/day (CPZ + VEN20) for 5 weeks. Body weight was measured twice weekly. Behavioral tests were performed to evaluate depression-like behaviors and working memory during the fifth week.

### Behavioral Tests {#sec5}

The locomotor activity, spatial working memory (Y-maze spontaneous alternation), and depression-like behaviors such as tail suspension test (TST) and forced swim test (FST) were performed during the fifth week after treatment. Only one behavioral test was carried out in each day with the order like this: (1) locomotor activity, (2) Y-Maze, (3) the first FST, (4) TST, and (5) the second FST.

#### Locomotor Activity Test {#sec6}

The spontaneous locomotor activity was measured using a light beam system as described previously ([@ref53]). Briefly, each mouse was put in a transparent cage (40 cm × 40 cm × 25 cm) equipped with photo beams near the bottom of the cage. After 1-min adaptation, the frequency of photo-beam interruptions during the subsequent 5-min period was recorded to measure total movements, including both horizontal and vertical movements.

#### Y-Maze Test {#sec7}

The working memory was assessed by recording spontaneous alternation in a Y-maze apparatus. It is the natural tendency of rodents to explore a novel environment ([@ref20]). The normal mice will remember the arm they have already explored and will enter one of the other arms of the maze. The Y-maze has three arms, named A, B, and C. Mice were placed individually onto the end of one arm (A) and allowed to explore all three arms freely for 8 min. After the first 2 min for habituation, the alternations between arms were recorded during the remained 6 min using Anymaze^™^ behavioral analyzing software ([@ref16]). The alternation defined as the overlapping entrance sequence (e.g., ABC, BCA) was calculated as the percentage: alternation % = (number of alternations)/(total number of arm entries − 2) × 100 ([@ref52]). Total arm entries were used as an index of ambulatory activity. Mouse with five or fewer arm entries in 6 min was excluded from the data analysis.

#### TST and FST {#sec8}

FST and TST have been commonly employed to evaluate the depression-like behaviors and antidepressant efficacy in the rodent models ([@ref33]). In these tests, a mouse was submitted to an inescapable aversive situation, alternating periods of activity and immobility to reflect "behavioral despair" ([@ref38]). In FST, mice were placed in a Plexiglas cylinder (10 cm internal diameter, 20 cm in height) filled with water (25--26°C temperature and 10 cm in height). Each mouse was allowed to swim for a 6-min session. The total immobility period during the last 4 min of the session was recorded. The immobility period was defined as the time while mice were utterly inactive or made movements only necessary to keep their heads above water. In TST, mice were suspended for 6 min in the air by taping their tails on a hanging bar. The immobility time during the 6 min was recorded. The immobility period was defined as the time while mice displayed no movement when suspended on the bar. All behaviors were recorded using a digital camcorder. The videos were analyzed by an observer blind to treatments using Anymaze^™^ behavioral software.

Histological and Immunohistochemical Staining {#sec9}
---------------------------------------------

After behavioral tests, all mice were euthanized with sodium pentobarbital (50 mg/kg, i.p.) and perfused intracardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Brains were then fixed overnight in 4% PFA. The fixed brains were subsequently rinsed three with PBS and cryoprotected in 30% sucrose in PBS at 4°C for 36 h. Three coronal sections (30 and 300 μm apart) between levels 1 and −1 mm from bregma were used for histological or immunohistochemistry staining. Luxol fast blue periodic acid-Schiff (LFB-PAS) (Sigma, St. Louis, MO, USA) staining was used to detect the severity of white matter demyelination in the CC ([@ref30]; [@ref22]). For immunohistochemical staining, floating brain sections were quenched for half hour in PBS with 0.3% hydroperoxide, followed by 1-h incubation in blocking solution containing 10% host serum in PBS at room temperature (RT). The sections were subsequently incubated overnight with the primary antibodies diluted in the blocking solution and incubated with the anti-goat or anti-rabbit biotin-conjugated secondary antibody (1:1,000; Vector Laboratories, Burlingame, CA) for 2 h at RT. The avidin-biotin complex kit (Vector Laboratories, Burlingame, CA) and 3,3-diaminobenzidine (DAB) chromogen (Sigma-Aldrich, St. Louis, MO) were used to visualize the staining. The brain sections were incubated at RT with the Alexa Fluor fluorescence secondary antibodies for immunofluorescent staining.

Antibodies {#sec10}
----------

Goat polyclonal antibody directed against myelin basic protein (MBP) (1:250; Santa Cruz Biotechnology, CA) was used to detect the myelin protein component ([@ref52]). Rabbit anti-Olig2 (1:200) and anti-nerve/glial antigen 2 (NG2) antibodies (1:200) (Millipore, Temecula, CA) were used as markers for cells in OL lineage and oligodendrocyte progenitor cells (OPCs), respectively ([@ref53]). Rat anti-glutathione S-transferase isoform π (GST-π, 1:500; Stressgen, Victoria, BC, Canada) was used to identify the mature OLs ([@ref53]). Olig2 and GST-π double labeling enabled to identify a subgroup of OL lineage cells with negative GST-π staining; these cells are considered either OPCs or immature OLs ([@ref52]). Rabbit polyclonal anti-CD11b (1:500; AbD Serotec, Raleigh, NC, USA) and goat anti-glial fibrillary acidic protein (GFAP) antibodies (1:1,000; Sigma, St. Louis, MO, USA) were used to identify activated microglia and astrocytes, respectively ([@ref52]).

Image Analysis {#sec11}
--------------

All images were obtained using an Olympus BX-51 light microscope or Olympus Confocal Laser Microscope 510 Meta. For each immunostaining analysis, digital images from three coronal sections were analyzed by two researchers blinded to the treatment using ImageJ software (version 6.1, Media Cybernetics, Inc., Silver Spring, MD). The software settings for imaging were kept identical among brain sections in each immunostaining. Demyelination in the CC was determined using a modified semiquantitative scale system with 0--4 points ([@ref9]): 0 (no demyelination), 1 (rare and focal demyelination), 2 (multiple focal demyelination), 3 (large or confluent demyelination), and 4 (large and confluent demyelination over 75% of CC). Demyelination in the cortical area was evaluated and expressed as the percentage of MBP-positive staining in a selected area vs. the staining in the corresponding area from control groups. GST-π and Olig2 immunostainings were measured from randomly selected areas within the CC in each section to quantify mature OLs and OL lineage cells, respectively. The cell numbers of CD11b-, GFAP-, and NG2-positive cells in the CC were evaluated using ImageJ software. Results were presented as the mean number of positive cells per square millimeter. Results from each animal were counted in three coronal sections, and the data are presented as the average of 16 mice per group.

Statistical Analysis {#sec12}
--------------------

Group differences were determined using two-way analyses of variance (ANOVA). Bonferroni *post hoc* analyses assessed statistical significance between groups. The nonparametric data were analyzed by the Kruskal-Wallis test and follow-up Dunn's multiple comparison test. The results were expressed as mean ± SEM. *p* \< 0.05 was considered statistically significant.

Results {#sec13}
=======

Effects of Venlafaxine on CPZ-Induced Behavioral Deficits {#sec14}
---------------------------------------------------------

### Locomotor Activity {#sec15}

As previously reported, mice receiving 5-week CPZ diet exhibited locomotor hyperactivity in a novel environment ([@ref48]; [@ref5]). We further examined whether venlafaxine treatment would moderate the behavioral abnormality. Locomotor activity level was measured by the frequency of photo-beam interruptions in a 5-min test period. Two-way ANOVA showed a main effect of CPZ (*F* = 15.76, *p* = 0.0002); CPZ exposure significantly increased the frequency of photo-beam interruption compared to regular diet ([Figure 1A](#fig1){ref-type="fig"}). Mice exposed to CPZ also had higher total arm entries in the Y-maze test compared to those with the regular diet (*F* = 15.57, *p* = 0.00021). Importantly, two-way ANOVA yielded a model-by-treatment interaction (*F* = 4.04, *p* = 0.02). Venlafaxine showed no effects on the frequencies of photo-beam interruption or arm entries (*p* \> 0.05) ([Figures 1A](#fig1){ref-type="fig"},[B](#fig1){ref-type="fig"}).

![The effects of venlafaxine on behaviors in normal and demyelinated mice. All mice were tested for **(A)** locomotor scores in the open field; **(B)** arm entries in the Y-maze test; **(C)** spontaneous alternative in the Y-maze test; **(D)** immobile time during the first trial of forced swim tests (FST-1); **(E)** immobile time during tail suspension test (TST); **(F)** immobile time during the second trial of forced swim tests (FST-2). Data were presented as means ± SEM (*n* = 16 in each group). \**p* \< 0.05 or \*\**p* \< 0.01 compared to the CTL; ^\#^*p* \< 0.05 or ^\#\#^*p* \< 0.01 compared to CPZ. CTL, control; CPZ, cuprizone; VEN5, venlafaxine 5 mg/kg/day; VEN20, venlafaxine 20 mg/kg/day.](fphar-10-00332-g001){#fig1}

### Working Memory {#sec16}

There was a significant model-by-treatment interaction (*F* = 4.54, *p* = 0.015) in the Y-maze spontaneous alternation test. CPZ mice displayed a substantial spatial memory deficit compared to the CTL group (*p* \< 0.003) ([@ref48]). The *post hoc* Scheffe's test showed a significantly lower alternation in the CPZ group (54.0%) compared to the CTL group (80.7%). Notably, there was a dose-dependent effect of venlafaxine on CPZ-induced spatial memory deficit, showing that only a higher dose was effective (CPZ + VEN20, *p* = 0.02) ([Figure 1C](#fig1){ref-type="fig"}).

### Depression-Like Behaviors {#sec17}

In the first FST (FST-1), there was no significant difference in immobility time among groups ([Figure 1D](#fig1){ref-type="fig"}), suggesting that neither venlafaxine nor CPZ elicited "despair behaviors" after 5-week treatment. Two-way ANOVA revealed significant model-by-treatment interaction in the TST on day 2 (*F* = 3.41, *p* = 0.03). The CPZ group had a significantly prolonged immobility time compared to the CTL group (*p* = 0.0137). There were no differences among CTL and venlafaxine suggesting that venlafaxine reversed the prolonged immobility time caused by CPZ ([Figure 1E](#fig1){ref-type="fig"}). Interestingly, there was a significant model-by-treatment interaction (*F* = 4.24, *p* = 0.02) and a main effect for CPZ (*F* = 8.84, *p* = 0.005) in the second FST (FST-2). The CPZ groups had a significantly longer immobility time compared to CTL group (*p* = 0.00063); alternatively, venlafaxine treatments decreased the immobility times compared to CPZ group (CPZ + VEN5 vs. CPZ, *p* = 0.015, CPZ + VEN20 vs. CPZ, *p* = 0.035) ([Figure 1F](#fig1){ref-type="fig"}).

Effects of Venlafaxine on CPZ-Induced Demyelination in the CC and the Cerebral Cortex {#sec18}
-------------------------------------------------------------------------------------

Five-week CPZ treatment causes extensive demyelination in the CC and the cerebral cortex of C57BL/6 mice ([@ref48]) ([Figure 2A](#fig2){ref-type="fig"}). The LFB-PAS staining showed significantly higher demyelination scores in the CC in CPZ compared to CTL groups in the CC ([Figure 2B](#fig2){ref-type="fig"}, *p* \< 0.0001). Venlafaxine in the regular diet mice had no effect on the myelination status. On the contrary, a high dose of venlafaxine (20 mg/kg/day) significantly alleviated CPZ-induced demyelination in the CC, while lower dose of venlafaxine (5 mg/kg/day) failed to show any improvement ([Figure 2B](#fig2){ref-type="fig"}). The percentage of MBP-positive stained area showed that mice exposed to CPZ had a significant loss of MBP compared to the CTL mice in the cerebral cortex; venlafaxine treatment did not change the percentage of MBP staining in mice on the regular diet. High dose of venlafaxine (20 mg/kg/day) significantly reduced the cortical demyelination caused by CPZ (*p* \< 0.05). Altogether, these findings suggest that venlafaxine exerted neuroprotective effects on myelin sheaths in both the CC and cortical areas against CPZ-induced demyelination in a dose-dependent fashion ([Figure 2C](#fig2){ref-type="fig"}).

![The effects of venlafaxine on myelin integrity in normal and demyelinated mice. **(A)** Representative images of Luxol fast blue and periodic acid-Schiff (LFB-PAS) staining in the corpus callosum (CC) and myelin basic protein (MBP) immunostaining in the CC and cortex; **(B)** demyelination score based on LFB-PAS staining in the CC; **(C)** Quantitative analysis of cortical demyelination measured by percentage of MBP immunostaining area in the frontal cortex in each group. Data are presented as mean ± SEM (*n* = 16 mice per group). The LFB-PAS score was analyzed by the Kruskal-Wallis test (Dunn's multiple comparison test). MBP staining data were analyzed by two-way ANOVA followed by Bonferroni *post hoc* analyses. Significances among different conditions are indicated as below: \*\**p* \< 0.01 or \*\*\**p* \< 0.001 compared to the CTL; ^\#^*p* \< 0.05 or ^\#\#^*p* \< 0.01 compared to CPZ. ^&&^*p* \< 0.01 compared to CPZ + VEN5. Scale bar represents 100 μm; CTL, control; CPZ, cuprizone; VEN5, venlafaxine 5 mg/kg/day; VEN20, venlafaxine 20 mg/kg/day.](fphar-10-00332-g002){#fig2}

Effects of Venlafaxine on Oligodendrocytes in the CPZ-Induced Demyelination {#sec19}
---------------------------------------------------------------------------

The number of total OL lineage cells (Olig2+) in the CC was significantly reduced in the CPZ and CPZ + VEN5 groups, compared to the CTL groups ([Figures 3A](#fig3){ref-type="fig"}--[C](#fig3){ref-type="fig"}); however, CPZ + VEN20 groups demonstrated a significantly higher number of Olig2+ cells compared to the CPZ and CPZ + VEN5 groups ([Figures 3A](#fig3){ref-type="fig"}--[C](#fig3){ref-type="fig"}). The Olig2+ cells were further categorized into GST-π− and GST-π+ cells using Olgi2 and GST-π double labeling. The majority of Olig2+ cells (\~80%) were mature OLs (GST-π+) in the CC in CTL groups; there was only 15% of Olig2+ cells were GST-π+ in CPZ group. A high dose of venlafaxine significantly increased the percentage of the GST-π+ cells to 35% ([Figure 3D](#fig3){ref-type="fig"}). The Olig2+/GST-π− cells were significantly increased in all CPZ groups, and venlafaxine seemed did not alter the cell numbers in CPZ groups ([Figure 3E](#fig3){ref-type="fig"}). The number of NG2+ OPCs was significantly increased in CPZ-exposed mice compared to CTL groups (*p* \< 0.001). Conversely, venlafaxine treatment significantly reduced the number of NG2+ in the CC in the CPZ-exposed mice ([Figure 4A](#fig4){ref-type="fig"}). A high dose of venlafaxine was more efficient compared to a low dose of venlafaxine ([Figure 4B](#fig4){ref-type="fig"}).

![Venlafaxine reduced mature OL loss in the corpus callosum (CC) of cuprizone-exposed C57BL/6 mice. **(A)** Representative images of Olig2, GST-π, and Olig2/GST-π double labeling in the CC areas; **(B)** the double labeling of Olig2 and GST-π at high magnification; **(C)** quantitative analysis of the total number of Olig2+ cells; **(D)** the percentage of Olig2+/GST-π+ cells in the CC in each group; **(E)** quantitative analysis of the Olig2+/GST-π− cells in the CC in each group. Data are presented as mean ± SEM (*n* = 16 mice per group). The data were analyzed by two-way ANOVA followed by Bonferroni *post hoc* analyses. Significances among different conditions are indicated as below: \*\**p* \< 0.01 compared to the CTL; ^\#\#^*p* \< 0.01 compared to CPZ and ^&^*p* \< 0.05 compared to CPZ + VEN5. Scale bar represents 100 μm; CTL, control; CPZ, cuprizone; VEN5, venlafaxine 5 mg/kg/day; VEN20, venlafaxine 20 mg/kg/day.](fphar-10-00332-g003){#fig3}

![Venlafaxine decreased oligodendrocyte (OL) progenitor cell (OPC) accumulation in the corpus callosum (CC) of cuprizone-exposed C57BL/6 mice. **(A)** Representative images of NG2 immunostaining in the CC areas; **(B)** quantitative analysis of the number of NG2+ cells in the CC in each group. The results are presented as mean ± SEM (*n* = 16 mice per group). The data were analyzed by two-way ANOVA followed by Bonferroni *post hoc* analyses. Significances among different conditions are indicated as below: \*\**p* \< 0.01 compared to the CTL; ^\#\#^*p* \< 0.01 compared to CPZ, and ^&&^*p* \< 0.01 compared to CPZ + VEN5. Scale bar represents 100 μm; CTL, control; CPZ, cuprizone; VEN5, venlafaxine 5 mg/kg/day; VEN20, venlafaxine 20 mg/kg/day.](fphar-10-00332-g004){#fig4}

Venlafaxine Reduces Inflammatory Changes in the CC {#sec20}
--------------------------------------------------

In the present study, we used CD11b and GFAP immunostainings to identify activated microglia and astrocytes, respectively ([Figure 5A](#fig5){ref-type="fig"}). There was a significantly increased number of CD11b+ cells in the CC of CPZ-exposed mice compared to the CTL mice (*p* \< 0.001) ([Figure 5B](#fig5){ref-type="fig"}). Alternatively, venlafaxine produced a dramatic dose-dependent reduction in the number of CD11b+ cells in the CPZ-exposed mice (*p* \< 0.001). The number of GFAP+ cells was also significantly higher in the CPZ-exposed mice than in the CTL mice, whereas venlafaxine counteracted to the CPZ effect (*p* \< 0.001) ([Figure 5C](#fig5){ref-type="fig"}). No dose-dependent effect was observed.

![Venlafaxine inhibited microglia and astrocyte activation in the corpus callosum (CC) of cuprizone-exposed C57BL/6 mice. **(A)** Representative images of CD11b and GFAP immunostaining in the CC areas; **(B)** quantitative analysis of the cell number of CD11b+ cells in the CC in each group. **(C)** Quantitative analysis of the cell number of GFAP+ cells in the CC in each group. Data are expressed as mean ± SEM (*n* = 16 mice per group). The data were analyzed by two-way ANOVA followed by Bonferroni *post hoc* analyses. Significances among different conditions are indicated as below: \*\**p* \< 0.01 compared to the CTL; ^\#\#^*p* \< 0.01 compared to CPZ, and ^&&^*p* \< 0.01 compared to CPZ + VEN5. Scale bar represents 100 μm; CTL, control; CPZ, cuprizone; VEN5, venlafaxine 5 mg/kg/day; VEN20, venlafaxine 20 mg/kg/day.](fphar-10-00332-g005){#fig5}

Discussion {#sec21}
==========

Venlafaxine is a SNRI antidepressant that increases the equimolar concentrations of 5-HT and NE at neuronal terminals ([@ref32]; [@ref23]). Venlafaxine also has neuroprotective and anti-inflammatory effects in the CNS and peripheral nervous system ([@ref42]; [@ref13]). Moreover, a few clinical studies reported the cognitive effect of venlafaxine in patients with MDD ([@ref40]; [@ref7]). Nevertheless, it is difficult to determine whether cognitive improvements due to venlafaxine in MDD are due to the improvement of cognitive processes *per se* or because of improvement of depressive symptoms as well, because the severity of cognitive impairment is highly associated with the severity and subtypes of MDD ([@ref37]). Thus, the purpose of this research is to explore venlafaxine effect on cognitive and depression-like processes with respect to demyelination and inflammatory processes in the brain. The CPZ-induced demyelination mouse model was utilized to investigate cognitive impairments and mood symptoms associated with OL cell death and acute demyelination and associated neuroinflammation ([@ref39]). Y-maze testing evaluated the cognitive effects of venlafaxine on CPZ-induced demyelination; a series of FST and TST behavioral tests assessed depression-like behaviors.

Notably, no depression-like behaviors were observed in all groups in the first FST following Y-maze test, suggesting that CPZ-induced cognitive impairment occurred in the absence of depression ([@ref4]). Venlafaxine was found to improve working memory deficits in mice exposed to CPZ in a dose-specific manner. A high dose of venlafaxine attenuated the cognitive impairment of CPZ-treated mice; a lower dose of venlafaxine failed to reduce abnormalities in working memory. Venlafaxine's effect on the cognitive process is likely independent to its effect on spontaneous depression. As it is accepted that carrying out FST or TST imposes significant stress to the testing animals, repeated expose to FST or TST is considered to generate a chronic depression model ([@ref36]). Mice receiving regular diet showed consistent immobility time across FST1-TST-FST2 processes, while CPZ-fed groups exhibited increased immobile time on TST and FST2. Venlafaxine treatment reversed the immobile time in the second FST. The results indicate that CPZ exposure for 5 weeks may not lead to an early depression-like behavior. However, demyelination and neuroinflammation caused by CPZ may alter the neurobiology of resilience and make animals more vulnerable to psychosocial stress ([@ref29]). Venlafaxine's cognitive benefit may be partially due to its protective effects against chronic psychosocial stress (i.e., repeated exposure to stressors -- FST and TST).

Venlafaxine also improved myelin integrity on CPZ-induced demyelination. Again, the effect was dose specific, a higher dose more beneficial than a lower one. In consistent with previous findings ([@ref25]), CPZ feeding for 5 weeks induced OLs apoptosis and acute demyelination. On the contrary, high dose of venlafaxine reduced demyelination in the CC in the cortical areas. Venlafaxine's effect on myelination mirrored the Y-maze results, suggesting that cognitive improvement can be associated with venlafaxine's therapeutic effect on myelin integrity. Venlafaxine's antidepressant effect seems independent to its myelin protection and anti-inflammatory effect.

Both mature, myelin-producing OLs and immature cell lines (OPC) belong to OL lineage and have a crucial role in myelination. OPCs proliferate and migrate to repair demyelinated lesion sites in MS and MDD ([@ref19]). Remyelination can be affected due to a hindered differentiation of these immature cells into myelin-producing, mature OLs ([@ref21]). Additionally, OPCs are capable of differentiating into mature OLs and astrocytes ([@ref10]). These cells are the primary source of myelin repair and are upregulated following OL cell death ([@ref25]) ([@ref43]).

Venlafaxine protected OL lineage cells in the present study. Specifically, a high dose of venlafaxine attenuated the depletion of mature OLs (i.e., Olig2+/GST-π+ cells) observed in the CPZ group. A high dose of venlafaxine also normalized compensatory increase of immature (i.e., NG2+) cells. Thus, the attenuated NG2+ cell numbers in CPZ + VEN20 groups may be due to preventing mature OL death as opposed to promoting the differentiation of OPCs.

A protective role of venlafaxine may also be attributed to reducing neuroinflammatory processes. Microglia, resident immune cells of the CNS, may polarize into a pro-inflammatory M1 phenotype or regenerative M2 phenotype ([@ref17]). Increased microglial expression in the CPZ model acts as a marker for neuroinflammation ([@ref52]). It is no surprise that a high dose of venlafaxine significantly reduced the number of CD11b (i.e., microglia) and GFAP (i.e. astrocytes) signal in the present study. Venlafaxine was reported to possess strong immunoregulatory activities ([@ref13]). Its ability to modulate microglia and macrophage activation in animal models of neurological disorders was also reported ([@ref54]). Venlafaxine's anti-inflammatory effect found that this study aligns with earlier reports ([@ref24]). Further work is required to elucidate this mechanistic relationship; however, in the present study, we provide original evidence regarding the role of venlafaxine on attenuating microglia-mediated inflammation and demyelination.

Summary {#sec22}
=======

Here, we provide the evidence, for the first time, about a comparable protective effect of venlafaxine on myelin integrity and cognitive function in a demyelination mouse model. This study suggests that venlafaxine can be a medication of choice for depression and anxiety in MS. Venlafaxine's strong neuroprotective and anti-inflammatory effects on myelin and OLs may provide extra therapeutic benefits to MS patients by altering the inflammation and demyelination process. Clinical studies with MS patients are needed to validate the findings and assess psychological and pathological progress.
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